RTP Mobile Logo
Select Publications

Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract

Garcia-Manero G et al. A phase III placebo-controlled trial of CC-486 in patients with red blood cell transfusion-dependent (RBC-TD) anemia and thrombocytopenia due to IPSS lower-risk myelodysplastic syndromes (LR-MDS). EHA 2020;Abstract S180.

Garcia-Manero G et al. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J of Hematol 2020;95(11):1399-420. Abstract

Nazha A et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia 2016;30(11):2214-20. Abstract

├śrskov AD et al. Hypomethylation and up-regulation of PD-1 in T cells by azacitidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015;6(11):9612-26. Abstract

Richard-Carpentier G et al. Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). ASH 2019;Abstract 678.

Sallman DA et al. Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). ASH 2019;Abstract 676.

Sallman DA et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: Ongoing phase 1b results. ASH 2019;Abstract 569.

Sekeres MA et al. Efficacy and safety of pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes (MDS) from study P-2001 (NCT02610777). ASH 2020;Abstract 653.

Suragani RNVS et al. Transforming growth factor-╬▓ superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nature Med 2014;20(4):408-14. Abstract

Yang H et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014;28(6):1280-8. Abstract

Zeidan AM et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine for the treatment of relapsed/refractory myelodysplastic syndrome. ASH 2020;Abstract 3109.